TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12204864

Group type: EXPERIMENTAL
Intervention: Smoking intervention
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Men who quit at the beginning of the LHS
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Women who quit at the beginning of the LHS
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Men continuing to smoke throughout the 11 years
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Women continuing to smoke throughout the 11 years
Number of subjects: 77

Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sustained quitters
Number of subjects: 77
Study: 9814452

Group type: EXPERIMENTAL
Intervention: Dietary milk supplementation (D-4 glasses of milk/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3-1000 mg/day in two divided doses)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7658265

Group type: EXPERIMENTAL
Intervention: 99mTc glucoheptonate renal scan (GHS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Renal ultrasonography (RUS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Voiding cystourethrography (VCUG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined GHS and VCUG
Number of subjects: 50
Study: 2713213

Group type: EXPERIMENTAL
Intervention: Osmet (osmotic pumping device)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tablet formulation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous nitrendipine
Number of subjects: 9
Study: 70929

Group type: EXPERIMENTAL
Intervention: UV-light alone (313 nm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trioxsalen plus UV-light (365 nm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coal tar plus UV-light (365 nm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: UV-light alone (365 nm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coal tar alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: UV-light (405 nm)
Number of subjects: 0
Study: 30295425

Group type: EXPERIMENTAL
Intervention: FIN-RACo + IFX
Number of subjects: 99

Group type: COMPARATOR
Intervention: FIN-RACo + placebo
Number of subjects: 99
Study: 29066265

Group type: EXPERIMENTAL
Intervention: Evolocumab plus standard of care (SOC)
Number of subjects: 440

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Evolocumab plus SOC
Number of subjects: 440
Study: 25361982

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)/leucovorin
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 1254
Study: 24114862

Group type: EXPERIMENTAL
Intervention: Contingent group (n=39) earned vouchers based on video confirmation of breath CO ≤ 4 ppm
Number of subjects: 77

Group type: COMPARATOR
Intervention: Noncontingent group (n=38) earned vouchers independent of CO levels
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups (contingent and noncontingent)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Contingent group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study: 21593118

Group type: EXPERIMENTAL
Intervention: 1 × 750 mg dose of metyrapone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 × 750 mg dose of metyrapone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19331224

Group type: EXPERIMENTAL
Intervention: 10,000 IU epoetin-alpha thrice weekly
Number of subjects: 399

Group type: COMPARATOR
Intervention: Control group (no epoetin-alpha)
Number of subjects: 399
Study: 16504956

Group type: EXPERIMENTAL
Intervention: 15% sage spray (140 microl sage extract per dose)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 15276496

Group type: EXPERIMENTAL
Intervention: CABG plus transmyocardial revascularization (CABG/TMR)
Number of subjects: 218

Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 218
Study: 10904284

Group type: COMPARATOR
Intervention: Enalapril (35 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Losartan (175 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Enalapril + Losartan (15 mg + 100 mg/day)
Number of subjects: 46
Study: 9060552

Group type: EXPERIMENTAL
Intervention: prednimustine 200 mg/m2/d for 5 days per month for 18 months
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: interferon alfa 5 MU/d for 3 months then 5 MU three times per week for 15 months
Number of subjects: 193

Group type: COMPARATOR
Intervention: no initial treatment
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: prednimustine
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: interferon alfa
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: progression within 1 year
Number of subjects: 193
Study: 8462390

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2939208

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 28919130

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR) + treatment-as-usual (TAU)
Number of subjects: 96

Group type: COMPARATOR
Intervention: treatment-as-usual (TAU) alone
Number of subjects: 96
Study: 30201930

Group type: EXPERIMENTAL
Intervention: Workplace sitting-reduction intervention with activity tracker
Number of subjects: 153

Group type: COMPARATOR
Intervention: Workplace sitting-reduction intervention without activity tracker
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Sitting reduction (h/10 h at work)
Number of subjects: 153
Study: 27959713

Group type: EXPERIMENTAL
Intervention: Low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 12 months
Number of subjects: 2124

Group type: EXPERIMENTAL
Intervention: Very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or 12 months
Number of subjects: 2124

Group type: COMPARATOR
Intervention: Standard therapy with a dose-adjusted vitamin K antagonist plus DAPT for 1, 6, or 12 months
Number of subjects: 2124
Study: 24814486

Group type: EXPERIMENTAL
Intervention: Platinum chromium-based everolimus-eluting stent (PtCr-EES)
Number of subjects: 3755

Group type: COMPARATOR
Intervention: Cobalt chromium-based zotarolimus-eluting stent (CoCr-ZES)
Number of subjects: 3755
Study: 22514244

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 4752

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 4752
Study: 20600481

Group type: EXPERIMENTAL
Intervention: Intradermal delivery using BD microneedle technology at 1/4 the IM antigen dose
Number of subjects: 66

Group type: COMPARATOR
Intervention: Epidermal delivery (BD skin abrader)
Number of subjects: 66
Study: 18826994

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-directive counselling
Number of subjects: 27
Study: 15947110

Group type: COMPARATOR
Intervention: Epirubicin (EPI)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Epirubicin plus Tamoxifen (EPI-TAM)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) and Epirubicin plus Tamoxifen (EPI-TAM)
Number of subjects: 211
Study: 12067231

Group type: EXPERIMENTAL
Intervention: Pigment epithelium-derived factor (PEDF) in CSF
Number of subjects: 15
Study: 10832363

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy using the Laparolift device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional laparoscopy with pneumoperitoneum
Number of subjects: 30
Study: 9489251

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave lithotripsy (ESWL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 35
Study: 8443746

Group type: EXPERIMENTAL
Intervention: Intrahepatic floxuridine (FUDR) combined with systemic 5-fluorouracil (5-FU) and leucovorin (LV)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy after liver metastasis resection
Number of subjects: 21
Study: 3493523

Group type: EXPERIMENTAL
Intervention: 16,16 dm prostaglandin E2, 1 microgram/kg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 29873282

Group type: EXPERIMENTAL
Intervention: Adsay method
Number of subjects: 165

Group type: COMPARATOR
Intervention: Verbeke method
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Lymph node metastasis (LNM)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: >15 lymph nodes evaluated
Number of subjects: 165
Study: 26227080

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham acupuncture (n = 8)
Number of subjects: 17
Study: 25044535

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2128
Study: 22414964

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium iron EDTA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Iron polymaltose
Number of subjects: 10
Study: 19884008

Group type: EXPERIMENTAL
Intervention: Metronomic administration of pegylated liposomal-doxorubicin (PLD) at a dosage of 20mg/m² i.v. every two weeks
Number of subjects: 52
Study: 19082804

Group type: EXPERIMENTAL
Intervention: Zengse Pill (ZSP), 5 pills per dose, 3 times daily for 3 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cobamamide (2 tablets) orally and Psoralea tincture externally thrice a day for 3 months (Control group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Zengse Pill (ZSP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (Cobamamide and Psoralea tincture)
Number of subjects: 65
Study: 16670650

Group type: EXPERIMENTAL
Intervention: Parent education and behavior management intervention (20-week manual-based)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Parent education and counseling intervention (20-week manual-based)
Number of subjects: 105
Study: 14514497

Group type: EXPERIMENTAL
Intervention: Antidepressants (nortriptyline or fluoxetine)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 10772083

Group type: EXPERIMENTAL
Intervention: 3-drug arm (rifabutin 600 mg daily, ethambutol 15 mg/kg daily, clarithromycin 1000 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-drug arm (rifampin 600 mg, ethambutol 15 mg/kg daily, clofazimine 100 mg daily, ciprofloxacin 750 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-drug arm
Number of subjects: 0
Study: 8908465

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study: 29544711

Group type: EXPERIMENTAL
Intervention: Depression Care for People with Cancer (DCPC)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 642
Study: 26669913

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 206
Study: 24919837

Group type: EXPERIMENTAL
Intervention: Bosutinib 50 to 600 mg orally with food
Number of subjects: 870
Study: 22727709

Group type: EXPERIMENTAL
Intervention: Duloxetine (60-120 mg/d)
Number of subjects: 126
Study: 20465434

Group type: EXPERIMENTAL
Intervention: Olive oil enriched with n-3 PUFA (6.5 ml daily for 12 months)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11
Study: 17650833

Group type: EXPERIMENTAL
Intervention: Ciclesonide, 200 microg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16115902

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 5187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5187
Study: 12140346

Group type: EXPERIMENTAL
Intervention: Monthly telephone monitoring of psychological distress and home nursing visits
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1376
Study: 10192146

Group type: EXPERIMENTAL
Intervention: Urodilatin (20 ng/kg b.w./min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7755223

Group type: EXPERIMENTAL
Intervention: Recombinant glycoprotein vaccine (gD2 and gB2 with MF59 adjuvant) administered intramuscularly at 0, 1, and 6 months
Number of subjects: 137
Study: 2311148

Group type: EXPERIMENTAL
Intervention: Parent present at induction of anaesthesia
Number of subjects: 134

Group type: COMPARATOR
Intervention: Unaccompanied at induction of anaesthesia (control group)
Number of subjects: 134
Study: 532621

Group type: EXPERIMENTAL
Intervention: peroral fenylpropanolamin
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 31196798

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Radical Prostatectomy (RP)
Number of subjects: 647
Study: 27765479

Group type: EXPERIMENTAL
Intervention: Delirium observed in patients with AMS
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Neurological diseases as an etiology of AMS
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Hospital admission rates
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Mortality rates
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Infection as an etiology of AMS
Number of subjects: 822
Study: 25175495

Group type: EXPERIMENTAL
Intervention: 10 mg THC + 0 mg MPH
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg THC + 10 mg MPH
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg THC + 40 mg MPH
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MPH
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: THC and MPH combination
Number of subjects: 16
Study: 23411519

Group type: EXPERIMENTAL
Intervention: Long-centric occlusal pattern complete denture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Anatomic occlusal complete denture
Number of subjects: 10
Study: 20973909

Group type: EXPERIMENTAL
Intervention: Cope loop nephrostomy tube
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: FloSeal (gelatin matrix haemostatic sealant)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fascial stitch
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Postoperative pain analogue scores
Number of subjects: 31

Group type: COMPARATOR
Intervention: Operative time, estimated blood loss (EBL), postoperative stay, analgesics use, changes in creatinine and haemoglobin levels, postoperative SF-36 scores
Number of subjects: 31
Study: 19884550

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (10,000 U SC three times weekly if baseline Hb < 12.5 g/dL; 4,000 U SC three times weekly if baseline Hb >= 12.5 g/dL)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 301
Study: 17132120

Group type: EXPERIMENTAL
Intervention: Manual therapy (six sessions)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 38
Study: 16329348

Group type: EXPERIMENTAL
Intervention: Fexofenadine (120 mg/d for 10 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fluticasone (200 mcg/d for 10 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 11504959

Group type: EXPERIMENTAL
Intervention: IDV + ddI + d4T + hydroxyurea (HU) (600 mg twice daily)
Number of subjects: 202

Group type: COMPARATOR
Intervention: IDV + ddI + d4T
Number of subjects: 202

Group type: COMPARATOR
Intervention: IDV + ZDV + 3TC
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: IDV + ddI + d4T + HU
Number of subjects: 202
Study: 9267921

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) of abdominal muscles during expirium
Number of subjects: 13

Group type: COMPARATOR
Intervention: Unassisted efforts
Number of subjects: 13

Group type: COMPARATOR
Intervention: Therapist-assisted efforts
Number of subjects: 13
Study: 8102048

Group type: EXPERIMENTAL
Intervention: m-Chlorophenylpiperazine (MCPP) 0.1 mg/kg, intravenously, administered over 20 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: m-Chlorophenylpiperazine (MCPP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 3819290

Group type: EXPERIMENTAL
Intervention: Fieldmaster 50
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dicon AP2000
Number of subjects: 50
Study: 29554813

Group type: EXPERIMENTAL
Intervention: 1% Rimexolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.1% Dexamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.1% Fluorometholone
Number of subjects: 40
Study: 27156698

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 914

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Not applicable (overall findings)
Number of subjects: 914
Study: 26441182

Group type: EXPERIMENTAL
Intervention: Rehabilitation (supervised exercise program and advice about self‐management)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 214
Study: 24685786

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tea tree oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 60
Study: 20096432

Group type: EXPERIMENTAL
Intervention: Ghrelin (3 microg/kg) administered intravenously twice daily for 10 days
Number of subjects: 20
Study: 18234009

Group type: EXPERIMENTAL
Intervention: Pilsicainide (1 mg/kg) administration in Brugada syndrome patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (normal hearts)
Number of subjects: 16
Study: 16150147

Group type: EXPERIMENTAL
Intervention: Systematic home visits by nurses
Number of subjects: 5400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5400
Study: 12060444

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy following surgery (external vs. brachytherapy vs. combination therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 0
Study: 10029244

Group type: COMPARATOR
Intervention: MN rgp160
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MN rgp120
Number of subjects: 0
Study: 7601014

Group type: EXPERIMENTAL
Intervention: Spirapril ≥ 6 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spirapril (monotherapy or in combination with hydrochlorothiazide)
Number of subjects: 0
Study: 2167623

Group type: EXPERIMENTAL
Intervention: Vitamin E (900 international units daily for 6 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Beta-carotene (40 mg daily for 6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (matched control)
Number of subjects: 60
Study: 6755651

Group type: EXPERIMENTAL
Intervention: Antacid treatment (20 ml liquid antacid (Balancid) with a neutralizing capacity of 105 mmol, administered every second hour during waking hours for 7 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Antacid treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31778249

Group type: EXPERIMENTAL
Intervention: LBBAP
Number of subjects: 131

Group type: COMPARATOR
Intervention: RVSP
Number of subjects: 131
Study: 31544949

Group type: EXPERIMENTAL
Intervention: Belt electrode skeletal muscle electrical stimulation
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no electrical muscle stimulation)
Number of subjects: 94
Study: 30980733

Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 28407247

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (NHT) for RS < 11
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (NHT) for RS 11-25
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Chemotherapy (NCT) for RS 11-25
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Chemotherapy (NCT) for RS > 25
Number of subjects: 64

Group type: COMPARATOR
Intervention: NCT for RS 11-25
Number of subjects: 64
Study: 25304445

Group type: EXPERIMENTAL
Intervention: EASY Minds intervention (n = 27)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual school programme (n = 27)
Number of subjects: 54
Study: 23279388

Group type: EXPERIMENTAL
Intervention: Decision Board (DB)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-DB (Control)
Number of subjects: 81
Study: 21401686

Group type: EXPERIMENTAL
Intervention: Mindfulness practice using an audio CD of guided mindfulness
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 66
Study: 19401865

Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Self-reported two-day adherence
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Self-reported seven-day adherence
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Logistic regression analyses
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Mental health assessments (SF-36, CES-D, Perceived Stress Scale)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Attitudes toward HIV treatment
Number of subjects: 644
Study: 16567708

Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg/day
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg/day
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 14660050

Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 50